Investors Urged to Act as Class Action Files Against ADMA Biologics Inc.
Investor Alert: Pomerantz Law Firm Files Class Action Against ADMA Biologics Inc.
In a significant legal development, Pomerantz LLP has initiated a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA). This legal proceeding raises pressing concerns regarding potential securities fraud and other unlawful business activities involving the company and some of its executives. Investors who have incurred losses on their investments in ADMA are urged to reach out to Pomerantz to discuss their options regarding this class action.
Legal Details
The reminder comes alongside an important deadline for investors wishing to join the class action lawsuit. Those who purchased ADMA securities during the designated Class Period must act by August 10, 2026, to seek the appointment of a Lead Plaintiff in this case. Interested parties can obtain a copy of the complaint through the Pomerantz website, which also provides contact information for inquiries.
As context, the impetus for this legal action follows a critical short report published by Culper Research. On March 24, 2026, the report alleged that ADMA's reported revenue growth overstated the true condition of the company's financial health, attributing this discrepancy to a
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.